ADARx Pharma

News

The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.

Oncology

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.